MLTX Institutional Ownership

MoonLake Immunotherapeutics

Latest close $17.55 as of Aug 5, 2026

Create account to watch
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices. Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes. Filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro. The overall institutional consensus preview remains public. Compare plans.
Cross-institution intelligence

Institutional Research

Each institution is compared with its own prior filing, then the latest institution-level directions are compared for breadth.

Latest filing May 14, 2025
Public consensus preview Reduction leaning 38/100 institutional research score
1 tracked institution Latest filing May 14, 2025

1 reducing across 1 comparable institution.

Accumulating0
Unchanged0
Reducing1
Exited0

The overall consensus is public. Detailed holder comparisons, breadth history, ownership charts, and filing-specific signal analysis remain part of Investor and Pro research.

Price context

52-week position is market context and does not change the institutional consensus score.

52-week range data is not available for this security yet.

Tracked institutions

Public holder names and filing freshness. Detailed institution-by-institution analysis is locked.

Latest observation Mar 31, 2025
T. Rowe Price Associates May 14, 2025 filed
Detailed institutional research

See what is driving the consensus.

Unlock holder-by-holder changes, ownership history, breadth by period, disclosure timing, and filing-specific signal analysis.

Create free account Compare Investor and Pro

A free account adds watchlists and reveals tracker research gauges. Investor or Pro unlocks the detailed research above.

Beneficial ownership filing history

Showing 2 of 2 parsed filing(s)
Holder Observed / filed Reported change Shares Ownership Observation Filing Latest
T. Rowe Price Associates CIK0000080255 Mar 31, 2025 observed May 14, 2025 filed · 44d Schedule 13G amendment Reported reduction 3.0M -369.4K 12.00% 0.00 pts $39.07 $36.99 $17.55
T. Rowe Price Associates CIK0000080255 Dec 31, 2024 observed Feb 14, 2025 filed · 45d Initial Schedule 13G Initial Schedule 13G 3.3M 12.00% $54.15 $43.21 $17.55
Explore more institutional activity

Related research

Crawlable links to other securities with similar institutional consensus or recent multi-institution accumulation.

Similar research strength

CRAI CRA INTERNATIONAL INC 38/100 Reduction leaning DFIN DONNELLEY FINANCIAL SOLUTION 38/100 Reduction leaning CWEN Clearway Energy, Inc. 38/100 Reduction leaning RICK RCI HOSPITALITY HOLDINGS INC 38/100 Reduction leaning

Recent multi-institution accumulation

TVTX Travere Therapeutics, Inc. 2 accumulating Aug 6, 2026 PCVX VAXCYTE INC 2 accumulating Aug 6, 2026 VVX V2X INC 2 accumulating Aug 6, 2026 VSEC VSE CORP 3 accumulating Jul 31, 2026